# To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

> **NCT05483907** · PHASE2 · COMPLETED · sponsor: **Bridge Biotherapeutics, Inc.** · enrollment: 129 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** BBT-877
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05483907
- **Lead sponsor:** Bridge Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-12
- **Primary completion:** 2025-01-26
- **Final completion:** 2025-02-23
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05483907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05483907, "To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05483907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*